AUPH INVESTOR ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPH Pharmaceutical Investing
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma Pharmaceutical Investing
Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision Pharmaceutical Investing
Bristol Myers Squibb Receives European Commission Approval for Opdivo with Chemotherapy as First-Line Treatment for Patients with... Pharmaceutical Investing
Bristol Myers Squibb Receives European Commission Approval for Opdivo Plus Yervoy as First-Line Treatment for Patients with... Pharmaceutical Investing
Bristol Myers Squibb Receives European Commission Approval for Opdivo as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ?1% Pharmaceutical Investing
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings Pharmaceutical Investing
Resorts World Las Vegas Secures First-of-its-Kind Agreement With Allergan Aesthetics Pharmaceutical Investing
Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten Pharmaceutical Investing
Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial Pharmaceutical Investing
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma Pharmaceutical Investing
